CA: A Cancer Journal for Clinicians最新文献

筛选
英文 中文
Novel clinical trial designs emerging from the molecular reclassification of cancer 新的临床试验设计从癌症的分子重新分类出现
IF 254.7 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2025-01-22 DOI: 10.3322/caac.21880
Mina Nikanjam, Shumei Kato, Teresa Allen, Jason K. Sicklick, Razelle Kurzrock
{"title":"Novel clinical trial designs emerging from the molecular reclassification of cancer","authors":"Mina Nikanjam, Shumei Kato, Teresa Allen, Jason K. Sicklick, Razelle Kurzrock","doi":"10.3322/caac.21880","DOIUrl":"https://doi.org/10.3322/caac.21880","url":null,"abstract":"Next-generation sequencing has revealed the disruptive reality that advanced/metastatic cancers have complex and individually distinct genomic landscapes, necessitating a rethinking of treatment strategies and clinical trial designs. Indeed, the molecular reclassification of cancer suggests that it is the molecular underpinnings of the disease, rather than the tissue of origin, that mostly drives outcomes. Consequently, oncology clinical trials have evolved from standard phase 1, 2, and 3 tissue-specific studies; to tissue-specific, biomarker-driven trials; to tissue-agnostic trials untethered from histology (all <i>drug-centered designs</i>); and, ultimately, to <i>patient-centered</i>, N-of-1 precision medicine studies in which each patient receives a personalized, biomarker-matched therapy/combination of drugs. Innovative technologies beyond genomics, including those that address transcriptomics, immunomics, proteomics, functional impact, epigenetic changes, and metabolomics, are enabling further refinement and customization of therapy. Decentralized studies have the potential to improve access to trials and precision medicine approaches for underserved minorities. Evaluation of real-world data, assessment of patient-reported outcomes, use of registry protocols, interrogation of exceptional responders, and exploitation of synthetic arms have all contributed to personalized therapeutic approaches. With greater than 1 × 10<sup>12</sup> potential patterns of genomic alterations and greater than 4.5 million possible three-drug combinations, the deployment of artificial intelligence/machine learning may be necessary for the optimization of individual therapy and, in the near future, also may permit the discovery of new treatments in real time.","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"45 1","pages":""},"PeriodicalIF":254.7,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142991872","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Erectile dysfunction common within the first year after rectal cancer surgery 勃起功能障碍常见于直肠癌手术后的第一年
IF 503.1 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2025-01-20 DOI: 10.3322/caac.21879
Mike Fillon
{"title":"Erectile dysfunction common within the first year after rectal cancer surgery","authors":"Mike Fillon","doi":"10.3322/caac.21879","DOIUrl":"10.3322/caac.21879","url":null,"abstract":"&lt;p&gt;Colorectal cancer studies commonly use broad “umbrella” terms when discussing the outcomes of rectal cancer surgery and fail to ferret out the prevalence of the individual side effects. A study from Denmark has investigated the prevalence of erectile dysfunction (ED) 1 year after rectal cancer surgery, especially because survival rates for patients with rectal cancer have increased substantially on account of improvements in surgical, oncological, perioperative, and chemotherapy care.&lt;/p&gt;&lt;p&gt;However, this also has led to a growing risk of postsurgical complications, noted the study authors. For example, resection of the rectum can cause intraoperative nerve damage to the pelvic plexus nerves, which is believed to be the leading cause of postoperative sexual dysfunction.&lt;/p&gt;&lt;p&gt;The study appears in the &lt;i&gt;European Journal of Surgical Oncology&lt;/i&gt; (doi:10.1016/j.ejso.2024.108662).&lt;/p&gt;&lt;p&gt;According to the lead study author, Sebastian B. Hansen, PhD, who works at the Center for Perioperative Optimization in the Department of Surgery at the Copenhagen University Hospital in Denmark, the primary objective of this systematic review was to estimate the prevalence of ED within the first year after surgery for rectal cancer.&lt;/p&gt;&lt;p&gt;The second objective, Dr Hansen says, was to assess to what extent the surgical approach and techniques, including chemotherapy and radiotherapy, affected the occurrence of ED. “We wanted to investigate if the risk of developing sexual dysfunction following rectal cancer treatment was substantial, and if so, what contributed to it.” He adds that they were aware that the disease itself might contribute to the risk of sexual function impairment.&lt;/p&gt;&lt;p&gt;The researchers believe that their data overall are valid, even though the prevalence of moderate to severe ED varied between different studies. As a result, they are confident that “a great number of recovering rectal cancer patients are at risk.”&lt;/p&gt;&lt;p&gt;The overall confidence levels were low because even though the initial search resulted in 74 studies, only 22 studies were included in the analysis, as noted previously. The researchers wrote that this was due to “shortcomings” in the data reporting. For example, they noted that even though most of the studies used the 5- and 15-item versions of the International Index of Erectile Function, which allows for the stratification of ED degrees on a point score, the bulk of the studies reported only the mean or median results. They believe that this minimized their ability to gauge the level and intensity of ED. “The degree of ED is important since rectal cancer usually affects older men who (already) might have some deterioration in ED function at the time of diagnosis (and not an after effect from surgery),” they said.&lt;/p&gt;&lt;p&gt;Another key finding from the study was that overall, no significant difference was found with respect to the time of follow-up during the first year. However, the researchers speculate that a reason for the lower inc","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"75 1","pages":"5-6"},"PeriodicalIF":503.1,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21879","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142989952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inhibiting monoclonal antibody GDF-15 improves cancer cachexia symptoms 抑制单克隆抗体GDF-15改善癌症恶病质症状
IF 503.1 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2025-01-20 DOI: 10.3322/caac.21878
Mike Fillon
{"title":"Inhibiting monoclonal antibody GDF-15 improves cancer cachexia symptoms","authors":"Mike Fillon","doi":"10.3322/caac.21878","DOIUrl":"10.3322/caac.21878","url":null,"abstract":"&lt;p&gt;A new phase 2 study found that ponsegromab (Pfizer) helped with issues typically associated with cancer cachexia by suppressing weight loss and improving appetite and physical activity. Researchers found that the monoclonal antibody inhibited the serum level of growth differentiation factor 15 (GDF-15), which is associated with cachexia’s multifaceted syndrome. Currently, there are no medicines approved for treating cancer cachexia.&lt;/p&gt;&lt;p&gt;“We believe this study is a unique development elevating symptom science because it is a biomarker-driven symptom intervention,” says study author Eric Roeland, MD, an associate professor of medicine in the Division of Hematology/Medical Oncology at the Oregon Health and Science University’s Knight Cancer Institute Clinic in Portland, Oregon.&lt;/p&gt;&lt;p&gt;The study appears in &lt;i&gt;The New England Journal of Medicine&lt;/i&gt; (doi:10.1056/NEJMoa2409515).&lt;/p&gt;&lt;p&gt;This first in-patient, open-label, phase 1b study assessed the use of ponsegromab in 10 patients with cancer cachexia and elevated GDF-15 serum concentrations. Researchers found that ponsegromab improved the patients’ body weight and appetite, with lower serum GDF-15 levels and few adverse events (doi:10.1158/1078-0432.CCR-23-1631).&lt;/p&gt;&lt;p&gt;Dr Roeland says that a key reason for this latest study was the recognition that the GDF-15 cytokine binds to the glial cell–derived neurotrophic factor family receptor alpha-like protein (GFRAL) in the hindbrain. The GDF–GFRAL pathway is recognized as a main modulator of anorexia and body-weight regulation that potentially results in cachexia. These reported results are included in Part A of the study; Part B, an optional open-label extension, is ongoing.&lt;/p&gt;&lt;p&gt;The study was conducted from February through December 2023 with 187 patients: 40% had non–small cell lung cancer (74 patients), 32% had pancreatic cancer (59 patients), and 29% had colorectal cancer (54 patients). Patients were at least 18 years old with a median age of 67 years. Approximately two thirds of the participants were male; 37% of the participants were female.&lt;/p&gt;&lt;p&gt;The potential cachexia symptoms that the researchers investigated included a non–diet-related weight loss of 5% or more in the prior 6 months and an elevated serum GDF-15 level (≥1500 pg/mL). Patients with cachexia due to a nonmalignant illness, planned surgery, or weight-gaining prescribed drugs were excluded.&lt;/p&gt;&lt;p&gt;Ponsegromab was administered to patients at 74 sites in 11 countries. Four similarly sized groups underwent randomization. Every 4 weeks, one group (46 patients) received 100 mg subcutaneously, the second group (46 patients) received 200 mg subcutaneously, the third group (50 patients) received 400 mg subcutaneously, and 45 patients received a placebo, for a total of three doses each.&lt;/p&gt;&lt;p&gt;All 187 patients were treated, with 137 patients (73%) completing the 12-week trial. A similar number of patients in each group did not complete the study.&lt;/p&gt;&lt;p&gt;The primary end point was weight variati","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"75 1","pages":"2-4"},"PeriodicalIF":503.1,"publicationDate":"2025-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21878","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142989951","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer statistics, 2025: A hinge moment for optimism to morph into hope? 癌症统计,2025年:乐观转变为希望的关键时刻?
IF 503.1 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2025-01-16 DOI: 10.3322/caac.21877
Benjamin W. Corn MD, David B. Feldman PhD
{"title":"Cancer statistics, 2025: A hinge moment for optimism to morph into hope?","authors":"Benjamin W. Corn MD,&nbsp;David B. Feldman PhD","doi":"10.3322/caac.21877","DOIUrl":"10.3322/caac.21877","url":null,"abstract":"&lt;p&gt;Since 1951, the American Cancer Society has compiled and published data on an annual basis pertaining to the incidence and outcomes of most malignancies in the United States. This meticulous effort consistently manifests as one of the most cited articles in the literature, extensively referenced not only by oncologists but also by health scientists at large. The influence of this reporting is attributable to its comprehensiveness, readability, and the establishment of benchmarks for where we are, where we have been, and where we ought to be headed.&lt;/p&gt;&lt;p&gt;This year's article by Siegel et al.,&lt;span&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/span&gt; once again, provides important insights. Five-year relative all-cancer survival rates increased from 49% between 1975 and 1977 to approximately 69% between 2014 and 2020. Moreover, the general cancer mortality rate continues to fall. However, closer scrutiny reveals dramatic disparities. For instance, overall cancer incidence has declined in men but has been persistently rising in women. In addition, disproportionate cancer mortality is borne by Native Americans (particularly with regard to primary tumors of the colorectum, kidney, liver, lung, stomach, and uterine cervix), Black men (especially in the setting of prostate cancer), and Black women (for breast and uterine corpus cancers). Driving these disparities, Siegel et al. point to socioeconomic deprivation resulting from structural racism, including (but not limited to) inequities in access to screening and treatment.&lt;/p&gt;&lt;p&gt;The authors assert identifiable factors linked to other statistical trends as well. Although some of the apparent spikes in cancer burden may be attributable to a return to previous levels of screening and incidental detection after a dip in provider visits because of the coronavirus disease 2019 pandemic, simultaneously, there is concern about the growing popularity of electronic cigarettes and vaping. Meanwhile, although there has been an increase in overall cancer incidence among women, it is encouraging to learn that national human papillomavirus vaccination programs have gained traction and—when conjoined with punctilious screening as well as aggressive treatment of precursor lesions—have reduced the incidence of cervical cancer in people with a cervix. Furthermore, Siegel and colleagues comment on the association between increased research funding and improved rates of survival for hematopoietic and lymphoid malignancies. This contrasts with the underfunding of research regarding uterine corpus cancer, the only malignancy for which survival has steadfastly decreased during the past 4 decades.&lt;/p&gt;&lt;p&gt;Given the increased relative cancer survival rate, it is not uncommon for oncologists and the general public to express optimism. There is a theme that emerges from these numbers building on the prior reports of recent years: most cancers are potentially controllable, provided there is appropriate investment of research dollars, sufficient screening, and ac","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"75 1","pages":"7-9"},"PeriodicalIF":503.1,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21877","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142987014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer statistics, 2025 癌症统计,2025年
IF 503.1 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2025-01-16 DOI: 10.3322/caac.21871
Rebecca L. Siegel MPH, Tyler B. Kratzer MPH, Angela N. Giaquinto MSPH, Hyuna Sung PhD, Ahmedin Jemal DVM, PhD
{"title":"Cancer statistics, 2025","authors":"Rebecca L. Siegel MPH,&nbsp;Tyler B. Kratzer MPH,&nbsp;Angela N. Giaquinto MSPH,&nbsp;Hyuna Sung PhD,&nbsp;Ahmedin Jemal DVM, PhD","doi":"10.3322/caac.21871","DOIUrl":"10.3322/caac.21871","url":null,"abstract":"<p>Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths in the United States and compiles the most recent data on population-based cancer occurrence and outcomes using incidence data collected by central cancer registries (through 2021) and mortality data collected by the National Center for Health Statistics (through 2022). In 2025, 2,041,910 new cancer cases and 618,120 cancer deaths are projected to occur in the United States. The cancer mortality rate continued to decline through 2022, averting nearly 4.5 million deaths since 1991 because of smoking reductions, earlier detection for some cancers, and improved treatment. Yet alarming disparities persist; Native American people bear the highest cancer mortality, including rates that are two to three times those in White people for kidney, liver, stomach, and cervical cancers. Similarly, Black people have two-fold higher mortality than White people for prostate, stomach, and uterine corpus cancers. Overall cancer incidence has generally declined in men but has risen in women, narrowing the male-to-female rate ratio (RR) from a peak of 1.6 (95% confidence interval, 1.57–1.61) in 1992 to 1.1 (95% confidence interval, 1.12–1.12) in 2021. However, rates in women aged 50–64 years have already surpassed those in men (832.5 vs. 830.6 per 100,000), and younger women (younger than 50 years) have an 82% higher incidence rate than their male counterparts (141.1 vs. 77.4 per 100,000), up from 51% in 2002. Notably, lung cancer incidence in women surpassed that in men among people younger than 65 years in 2021 (15.7 vs. 15.4 per 100,000; RR, 0.98, <i>p</i> = 0.03). In summary, cancer mortality continues to decline, but future gains are threatened by rampant racial inequalities and a growing burden of disease in middle-aged and young adults, especially women. Continued progress will require investment in cancer prevention and access to equitable treatment, especially for Native American and Black individuals.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"75 1","pages":"10-45"},"PeriodicalIF":503.1,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21871","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142987012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors 聚二磷酸腺苷核糖聚合酶抑制剂在泛肿瘤中的作用综述
IF 254.7 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2025-01-10 DOI: 10.3322/caac.21870
Chadi Hage Chehade, Georges Gebrael, Nicolas Sayegh, Zeynep Irem Ozay, Arshit Narang, Tony Crispino, Talia Golan, Jennifer K. Litton, Umang Swami, Kathleen N. Moore, Neeraj Agarwal
{"title":"A pan-tumor review of the role of poly(adenosine diphosphate ribose) polymerase inhibitors","authors":"Chadi Hage Chehade, Georges Gebrael, Nicolas Sayegh, Zeynep Irem Ozay, Arshit Narang, Tony Crispino, Talia Golan, Jennifer K. Litton, Umang Swami, Kathleen N. Moore, Neeraj Agarwal","doi":"10.3322/caac.21870","DOIUrl":"https://doi.org/10.3322/caac.21870","url":null,"abstract":"Poly(adenosine diphosphate ribose) polymerase (PARP) inhibitors, such as olaparib, talazoparib, rucaparib, and niraparib, comprise a therapeutic class that targets PARP proteins involved in DNA repair. Cancer cells with homologous recombination repair defects, particularly <i>BRCA</i> alterations, display enhanced sensitivity to these agents because of <i>synthetic lethality</i> induced by PARP inhibitors. These agents have significantly improved survival outcomes across various malignancies, initially gaining regulatory approval in ovarian cancer and subsequently in breast, pancreatic, and prostate cancers in different indications. This review offers a comprehensive clinical overview of PARP inhibitor approvals, emphasizing their efficacy across different cancers based on landmark phase 3 clinical trials.","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"5 1","pages":""},"PeriodicalIF":254.7,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142939577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Underrepresentation of Hispanic women in science, technology, engineering, mathematics, and medicine 西班牙裔女性在科学、技术、工程、数学和医学领域的代表性不足
IF 254.7 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2025-01-09 DOI: 10.3322/caac.21875
Jovanka Gencel-Augusto, Natasha J. Minaya, Daniel E. Johnson, Jennifer R. Grandis
{"title":"Underrepresentation of Hispanic women in science, technology, engineering, mathematics, and medicine","authors":"Jovanka Gencel-Augusto, Natasha J. Minaya, Daniel E. Johnson, Jennifer R. Grandis","doi":"10.3322/caac.21875","DOIUrl":"https://doi.org/10.3322/caac.21875","url":null,"abstract":"Despite ongoing efforts to increase the number of women in science, technology, engineering, and mathematics (STEM) and in medicine, Hispanic women remain severely underrepresented in these fields. This disparity not only hinders scientific innovation and the delivery of culturally competent medical care but also perpetuates a systemic exclusion. Research specifically addressing the challenges faced by Hispanic women, the extent of underrepresentation in these disciplines, and strategies to mitigate these issues is sparce. The authors conducted a systematic analysis of peer-reviewed articles to address this gap. The findings reveal a stark underrepresentation of Hispanic women across all examined fields, particularly compared with White women. In addition, the underrepresentation persists when compared with Hispanic men, although the disparity is less pronounced. The authors identify ongoing disparities in promotion, compensation, and retention rates for Hispanic women; present data for barriers to entry and retention; and highlight existing programs and strategies aimed at addressing this underrepresentation. Finally, a framework is presented for future studies and actionable initiatives, and the broader implications of these findings for the field of oncology are highlighted.","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"2 1","pages":""},"PeriodicalIF":254.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142937702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Highlighting American Cancer Society-funded research in CA: A Cancer Journal for Clinicians 强调美国癌症协会资助的研究:临床医生癌症杂志
IF 254.7 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2025-01-09 DOI: 10.3322/caac.21876
Don S. Dizon, Christina M. Annunziata
{"title":"Highlighting American Cancer Society-funded research in CA: A Cancer Journal for Clinicians","authors":"Don S. Dizon, Christina M. Annunziata","doi":"10.3322/caac.21876","DOIUrl":"https://doi.org/10.3322/caac.21876","url":null,"abstract":"<p>Since 1946, the American Cancer Society (ACS) has invested more to find the causes and cures of cancer than any other single nongovernmental, not-for-profit organization. Each year, the ACS extends this support to investigators at institutions across the United States as part of its grants program, funding research for high school interns through world-renowned professors, including the ACS Professorship.</p>\u0000<p>We applaud the grantees supported by the ACS; and, as part of this commitment to acknowledge and highlight these investigators, <i>CA: A Cancer Journal for Clinicians</i> (<i>CA</i>), is proud to launch a new series, “American Cancer Society Research Award Spotlight.” As the flagship journal of the ACS, <i>CA'</i>s goal is to educate and widely disseminate their work, and their passions, to our diverse audience of cancer professionals. Topics will be of relevance to the broad audience of <i>CA</i>, and much of the work will be developed in consultation between the authors and the editorial board. Notably, we have not restricted the scope of articles to research directly supported by the ACS. Rather, we will work with the authors on a topic that drives their career, whether in the laboratory or in the clinic, reflecting timely issues within the scope of oncology or society at large.</p>\u0000<p>In addition to recipients of our standard grant mechanisms, <i>CA</i> will feature content from recipients of the ACS Professor Award, which recognizes key thought leaders who have made substantial contributions in cancer research.</p>\u0000<p>For more information around ACS-funded cancer research, please visit https://www.cancer.org/research/currently-funded-cancer-research.html for a full list of up-to-date funded research grants and current and past ACS professors.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"35 1","pages":""},"PeriodicalIF":254.7,"publicationDate":"2025-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142937734","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute myeloid leukemia management and research in 2025 2025年急性髓性白血病的管理和研究
IF 503.1 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2024-12-10 DOI: 10.3322/caac.21873
Hagop M. Kantarjian MD, Courtney D. DiNardo MD, Tapan M. Kadia MD, Naval G. Daver MD, Jessica K. Altman MD, Eytan M. Stein MD, Elias Jabbour MD, Charles A. Schiffer MD, Amy Lang MD, Farhad Ravandi MD
{"title":"Acute myeloid leukemia management and research in 2025","authors":"Hagop M. Kantarjian MD,&nbsp;Courtney D. DiNardo MD,&nbsp;Tapan M. Kadia MD,&nbsp;Naval G. Daver MD,&nbsp;Jessica K. Altman MD,&nbsp;Eytan M. Stein MD,&nbsp;Elias Jabbour MD,&nbsp;Charles A. Schiffer MD,&nbsp;Amy Lang MD,&nbsp;Farhad Ravandi MD","doi":"10.3322/caac.21873","DOIUrl":"10.3322/caac.21873","url":null,"abstract":"<p>The first 5 decades of research in acute myeloid leukemia (AML) were dominated by the cytarabine plus anthracyclines backbone, with advances in strategies including allogeneic hematopoietic stem cell transplantation, high-dose cytarabine, supportive care measures, and targeted therapies for the subset of patients with acute promyelocytic leukemia. Since 2017, a turning point in AML research, 12 agents have received regulatory approval for AML in the United States: venetoclax (BCL2 inhibitor); gemtuzumab ozogamicin (CD33 antibody–drug conjugate); midostaurin, gilteritinib, and quizartinib (fms-like tyrosine kinase 3 inhibitors); ivosidenib, olutasidenib, and enasidenib (isocitrate dehydrogenase 1 and 2 inhibitors); oral azacitidine (a partially absorbable formulation); CPX351 (liposomal encapsulation of cytarabine:daunorubicin at a molar ratio of 5:1); glasdegib (hedgehog inhibitor); and recently revumenib (menin inhibitor; approved November 2024). Oral decitabine-cedazuridine, which is approved as a bioequivalent alternative to parenteral hypomethylating agents in myelodysplastic syndrome, can be used for the same purpose in AML. Menin inhibitors, CD123 antibody–drug conjugates, and other antibodies targeting CD123, CD33, and other surface markers are showing promising results. Herein, the authors review the frontline and later line therapies in AML and discuss important research directions.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"75 1","pages":"46-67"},"PeriodicalIF":503.1,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21873","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142796814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cancer care for transgender and gender-diverse people: Practical, literature-driven recommendations from the Multinational Association of Supportive Care in Cancer 跨性别和性别多样化人群的癌症护理:来自多国癌症支持护理协会的实用、文献驱动的建议
IF 503.1 1区 医学
CA: A Cancer Journal for Clinicians Pub Date : 2024-12-09 DOI: 10.3322/caac.21872
Elizabeth J. Cathcart-Rake MD, Alexandre Chan PharmD, MPH, Alvaro Menendez MD, Denise Markstrom PharmD, Carla Schnitzlein DO, Yee Won Chong, Don S. Dizon MD
{"title":"Cancer care for transgender and gender-diverse people: Practical, literature-driven recommendations from the Multinational Association of Supportive Care in Cancer","authors":"Elizabeth J. Cathcart-Rake MD,&nbsp;Alexandre Chan PharmD, MPH,&nbsp;Alvaro Menendez MD,&nbsp;Denise Markstrom PharmD,&nbsp;Carla Schnitzlein DO,&nbsp;Yee Won Chong,&nbsp;Don S. Dizon MD","doi":"10.3322/caac.21872","DOIUrl":"10.3322/caac.21872","url":null,"abstract":"<p>In the United States, over 2 million individuals openly identify with a gender that differs from their sex assigned at birth. A cancer diagnosis is physically and psychologically taxing—and, in some, traumatic. However, for transgender and gender-diverse (TGD) people, many of whom have experienced discrimination in myriad health care settings, the challenges may be even greater. These recommendations focus on how best to deliver quality cancer care to transgender men (individuals who identify as men but were assigned female sex at birth), transgender women (individuals who identify as women but were assigned male sex at birth), and people who identify somewhere beyond this gender spectrum as nonbinary or using other terms, based on the available, albeit sparse, literature. This review broaches: (1) the epidemiology of cancer in TGD individuals, including the incidence of cancer and cancer-related mortality; (2) cancer center practices that are welcoming and affirming to TGD patients; (3) the need for awareness and intentionality in the spaces of diagnosis and treatment for cancer; (4) the inevitable conclusion that gender differences exist but much more needs to be learned about the impact of gender-affirming therapy, consisting of gender-affirming surgeries and gender-affirming hormone therapy, on cancer therapy; and (5) the efficacy and perceived safety of antineoplastic therapy and gender-affirming hormone therapy.</p>","PeriodicalId":137,"journal":{"name":"CA: A Cancer Journal for Clinicians","volume":"75 1","pages":"68-81"},"PeriodicalIF":503.1,"publicationDate":"2024-12-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.3322/caac.21872","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142793422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信